single5MG
TB-500
5MG Protocol
TB-500 5MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks based on research protocol
Reconstitution
3.0 mL BAC water
Supports wound healing and tissue repair via enhanced angiogenesis and cell migration
May help modulate fibrosis/inflammation indirectly in preclinical models
Generally well tolerated in veterinary observations cited on the page
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 500 mcg | 30 |
| 2 | Weeks 3–4 | 600 mcg | 36 |
| 3 | Weeks 5–8 | 750 mcg | 45 |
| 4 | Weeks 9–12 | 1000 mcg | 60 |
Inject once daily
8–12 weeks; optional extension to 16 weeks based on research protocol
The TB-500 protocol describes a repair-oriented mechanism based on thymosin biology. TB-500 is presented as the N-terminal active fragment of thymosin beta-4 (Ac-LKKTETQ), the portion associated with actin-binding and cell migration. By enhancing cell motility and supporting new blood-vessel formation, TB-500 is described as promoting angiogenesis and accelerating wound-healing processes in preclinical and veterinary literature. The page also references findings that injury sites exposed to thymosin fragments show improved collagen deposition and reduced overall healing time. An additional nuance included in the protocol is a prodrug hypothesis: TB-500 may be cleaved into a shorter, biologically active pentapeptide that drives part of its activity. Mechanistically, the protocol frames TB-500 as supporting coordinated regeneration signals across tissues, while emphasizing that robust, large-scale human safety and efficacy trials are not available.
Mild injection-site reactions (redness/tenderness)
Limited human safety data
no large-scale clinical trials specific to TB-500 described
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)